Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actionable fusions, the proto-oncogene is the drug target, the contributions to oncogenicity of the fusion partner have large...
Anna Borgenvik, Sean A. Misek, Daniel Christen et al.· bioRxiv· 1 citation
Findings identify coordinated suppression of a FOXM1-associated MCPH program as part of the GBM radiation response, while suggesting that the radiosensitizing effects of pharmacological FOXM1inhibition extend beyond this transcriptional axis.
L. Van Eupen, E. Etlioglu, K. Tabury et al.· bioRxiv· 0 citations
These findings reveal shared and virus-specific cellular processes driving OV resistance in GBM, providing a basis for strategies to overcome resistance.
T. Deconinck, T. Dierckx, F. De Smet et al.· bioRxiv· 0 citations
A large-scale international programme—the Human Cancer Models Initiative—is presented, which involved the generation of a resource of 665 next-generation models from 2,780 donors with 25 cancer types and integrated tumour–model whole genome, exome, methylome and transcriptome analyses.
Dina Elharouni, Mushriq Al-Jazrawe, Seongmin Choi et al.· Nature· 7 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.